Laboratory biomarkers and frailty: presentation of the FRAILOMIC initiative
MetadataShow full item record
The FRAILOMIC consortium (available at: http://www.frailomic.org/) was created and funded under the European FP7 framework in order to overcome these limitations. The consortium comprises seven small and medium-sized companies, six universities, two leading research centres, two hospital-based research groups and researches affiliated with the World Health Organization (WHO). The primary aim is to create a European network for developing clinical tools and validating biomarkers that can assist in the managed care of frailty. More specifically, a large number of molecular and biochemical biomarkers will be measured in as many as 75,000 participants, in order to develop predictive, diagnostic and prognostic models in the older general population and people at a higher risk of frailty. The analytical and diagnostic performance of these biomarkers will be compared against the current quality specifications to define whether the current techniques are suitable for use in this specific population. A selected set of biomarkers will then be validated prospectively and assessed to identify the best fit models, which will guide the development of panels of tests or risk estimation models to be used in the clinical setting. The homeostatic impairments of frailty will hence be assessed using a multidisciplinary approach within this network. Hopefully, the outcomes of this initiative will underline the important contribution of laboratory diagnostics for reducing the prevalence or severity of this increasingly frequent condition, thus resulting in large benefits for individuals, society and healthcare systems
Clinical Chemistry and Laboratory Medicine
Lippi, G., Jansen-Duerr, P., Viña, J., Durrance-Bagale, A., Abugessaisa, I., Gomez-Cabrero, D., Tegnér, J., Grillari, J., Erusalimsky, J., Sinclair, A. and Rodriguez-Manãs, L. (2015) 'Laboratory biomarkers and frailty: presentation of the FRAILOMIC initiative', Clinical Chemistry and Laboratory Medicine (CCLM), 53(10), pp.e253-e255
This article was published in Clinical Chemistry and Laboratory Medicine on 14 March 2015 (online), available at http://dx.doi.org/10.1515/cclm-2015-0147
Showing items related by title, author, subject and abstract.
Ambler, Nicola (University of Wales Institute Cardiff, 2012)Introduction: Prostate cancer is the second most commonly diagnosed cancer in men worldwide. Currently the biomarker used to diagnose and manage prostate cancer is Prostate Specific Antigen (PSA). Due to its associated ...
Scharhag, Jurgen; George, Keith; Shave, Rob; Urhausen, Axel; Kindermann, Wilfried (2008)At present, the risk of myocardial damage by endurance exercise is under debate because of reports on exercise-associated increases in cardiac biomarkers troponin and B-type natriuretic peptide (BNP); these markers are ...
Cerebrospinal fluid extracellular vesicle enrichment for protein biomarker discovery in neurological disease; multiple sclerosis Welton, Joanne Louise; Loveless, Samantha; Stone, Timothy; von Ruhland, Chris; Robertson, Neil; Clayton, Aled (Taylor & Francis, 2017-09-03)The discovery of disease biomarkers, along with the use of “liquid biopsies” as a minimally invasive source of biomarkers, continues to be of great interest. In inflammatory diseases of the central nervous system (CNS), ...